Biogen, a developer and manufacturer of innovative therapies for patients living with serious neurological, autoimmune and rare diseases, will stop producing drugs at its Cambridge, Massachusetts plant by year-end, as part of the companys focus on optimizing its global manufacturing network, according to reports.
The plant in Cambridge makes two multiple sclerosis drugs, Avonex and Plegridy, and the hemophilia A treatment Eloctate, using 2,000L-volume stainless steel bioreactors. Production of these drugs will be moved to larger sites in North Carolina and Europe.
The company is looking to sublease its bioprocessing operation in Kendall Square, but if another tenant cant be found, Biogen will shut down the 66,000-square-foot plant.